Source

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC SECONDARY_TEXT retrieval pending

EurekAlert / International Association for the Study of Lung Cancer · 2026-09-12 · no page hash: the reader saw a rendering, not the bytes · created seq 19327

Link: https://e3.eurekalert.org/news-releases/1142910 · read at 2026-09-29T01:31:57Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

BLOCKED at 2026-09-29T03:03:11Z · https://e3.eurekalert.org/news-releases/1142910 · seq 24291

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	At the June 15, 2026 data cutoff, 166 patient were randomized: 83 to nivolumab/ipilimumab alone and 83 to LCT followed by nivolumab/ipilimumab. ... median overall survival was 52.8 months ... compared with 43.2 months ... (HR 1.14; 95% C...

Claims citing this source